login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
NOVARTIS AG-SPONSORED ADR (NVS) Stock News
NYSE:NVS - New York Stock Exchange, Inc. -
US66987V1098
-
ADR
- Currency: USD
118.85
-0.82 (-0.69%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NVS Latest News, Press Relases and Analysis
All
Press Releases
5 hours ago - By: Benzinga
Earnings Outlook For Novartis
13 hours ago - By: Benzinga
- Mentions:
IHE
PJP
PPH
SPY
...
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
a day ago - By: Yahoo Finance
- Mentions:
JPM
C
WFC
GS
...
Inflation Data and Bank Earnings Kick Off a Crucial Test for Markets
4 days ago - By: The Motley Fool
- Mentions:
VYMI
VYM
NVDA
TM
This Dividend ETF Is Near Its Highest Level Ever -- Is It Too Late to Invest in It?
9 days ago - By: Zacks Investment Research
Here's Why Novartis (NVS) is a Strong Momentum Stock
6 days ago - By: CNBC
- Mentions:
UBS
LLY
Trump's 200% tariff threat leaves pharma firms scrambling with scenario planning
6 days ago - By: CNBC
- Mentions:
SBUX
Friday's big stock stories: What's likely to move the market in the next trading session
6 days ago - By: Yahoo Finance
- Mentions:
UBS
GMAB
JNJ
UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT
8 days ago - By: Yahoo Finance
- Mentions:
AAPG
VZ
6855
NOVN
Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance
8 days ago - By: The Motley Fool
- Mentions:
VEA
TM
$1,000 in VEA Could Turn Into $57,000
9 days ago - By: Bloomberg
Novartis Wins Approval for First Malaria Treatment for Babies
14 days ago - By: Bloomberg
Novartis Blockbuster Antibody Drug Fails in Late-Stage Trial
14 days ago - By: Yahoo Finance
- Mentions:
ATNM
PFE
NOVN
Actinium Highlights ATNM 400 Progress at SNMMI Conference
18 days ago - By: Yahoo Finance
- Mentions:
NOVN
RGLS
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
20 days ago - By: Investor's Business Daily
- Mentions:
AGN
RY
RY.CA
INCY
...
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
21 days ago - By: Investor's Business Daily
- Mentions:
BIIB
IONS
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Please enable JavaScript to continue using this application.